-
Mashup Score: 20Advancing Treatment for High-Risk Biochemical Recurrence Prostate Cancer: The ARASTEP Trial - Alexander Chehrazi-Raffle - 12 hour(s) ago
Zach Klaassen discusses the ARASTEP trial with Alex Chehrazi-Raffle. The trial focuses on patients with high-risk biochemical recurrence of prostate cancer, specifically those who show positive results on PSMA PET scans but are negative on conventional imaging. Dr. Chehrazi-Raffle explains that ARASTEP, a randomized phase 3 study, aims to evaluate the efficacy of combining androgen deprivation…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 22Advancing Treatment for High-Risk Biochemical Recurrence Prostate Cancer: The ARASTEP Trial - Alexander Chehrazi-Raffle - 30 day(s) ago
Zach Klaassen discusses the ARASTEP trial with Alex Chehrazi-Raffle. The trial focuses on patients with high-risk biochemical recurrence of prostate cancer, specifically those who show positive results on PSMA PET scans but are negative on conventional imaging. Dr. Chehrazi-Raffle explains that ARASTEP, a randomized phase 3 study, aims to evaluate the efficacy of combining androgen deprivation…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Advancing treatment for high-risk biochemical recurrence #ProstateCancer. @arafflemd @cityofhop sits with @zklaassen_md @GACancerCenter to discuss the #ARASTEP trial of ADT + Darolutamide vs. ADT alone on UroToday > https://t.co/zAiiCmALL0 https://t.co/jUwdBHGvr7
-
-
Mashup Score: 22Advancing Treatment for High-Risk Biochemical Recurrence Prostate Cancer: The ARASTEP Trial - Alexander Chehrazi-Raffle - 2 month(s) ago
Zach Klaassen discusses the ARASTEP trial with Alex Chehrazi-Raffle. The trial focuses on patients with high-risk biochemical recurrence of prostate cancer, specifically those who show positive results on PSMA PET scans but are negative on conventional imaging. Dr. Chehrazi-Raffle explains that ARASTEP, a randomized phase 3 study, aims to evaluate the efficacy of combining androgen deprivation…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Advancing treatment for high-risk biochemical recurrence #ProstateCancer. @arafflemd @cityofhop sits with @zklaassen_md @GACancerCenter to discuss the #ARASTEP trial of ADT + Darolutamide vs. ADT alone on UroToday > https://t.co/zAiiCmALL0 https://t.co/jUwdBHGvr7
-
-
Mashup Score: 22Advancing Treatment for High-Risk Biochemical Recurrence Prostate Cancer: The ARASTEP Trial - Alexander Chehrazi-Raffle - 3 month(s) ago
Zach Klaassen discusses the ARASTEP trial with Alex Chehrazi-Raffle. The trial focuses on patients with high-risk biochemical recurrence of prostate cancer, specifically those who show positive results on PSMA PET scans but are negative on conventional imaging. Dr. Chehrazi-Raffle explains that ARASTEP, a randomized phase 3 study, aims to evaluate the efficacy of combining androgen deprivation…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Advancing treatment for high-risk biochemical recurrence #ProstateCancer. @arafflemd @cityofhop sits with @zklaassen_md @GACancerCenter to discuss the #ARASTEP trial of ADT + Darolutamide vs. ADT alone on UroToday > https://t.co/zAiiCmALL0 https://t.co/jUwdBHGvr7
-
Advancing treatment for high-risk biochemical recurrence #ProstateCancer. @arafflemd @cityofhop sits with @zklaassen_md @GACancerCenter to discuss the #ARASTEP trial of ADT + Darolutamide vs. ADT alone on UroToday > https://t.co/zAiiCmALL0 https://t.co/jUwdBHGvr7